Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma

Japanese Journal of Clinical Oncology

Volumn 41, Issue 6, 2011, Pages 814-816

  Shitara, Kohei ^a   Yatabe, Yasushi ^a   Mizota, Ayako ^a   Sano, Tsuyoshi ^a   Nimura, Yuji ^a   Muro, Kei ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Epithelioid angiomyolipoma; Everolimus; Mtor

Indexed keywords

EVEROLIMUS;

ADULT; ANGIOMYOLIPOMA; ARTICLE; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; EPITHELIOID CELL; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT EPITHELIOID ANGIOMYOLIPOMA; NEEDLE BIOPSY; PELVIS; POSITRON EMISSION TOMOGRAPHY; STOMATITIS; TREATMENT RESPONSE; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANGIOMYOLIPOMA; ANTINEOPLASTIC AGENTS; EPITHELIOID CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; SIROLIMUS; TOMOGRAPHY, X-RAY COMPUTED; TOR SERINE-THREONINE KINASES;

EID: 79957876262     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr035     Document Type: Article

References (11)

1. Folpe AL. Neoplasms with perivascular epithelioid cell differentiation (PEComas). In: Fletcher CDM, Unni KK, Epstein J, Mertens F, editors. Pathology and Genetics of Tumours of Soft Tissue and Bone. Series: WHO Classication of Tumours. Lyon, France: IARC Press 2002;221-2.
2. Yamamoto T, Ito K, Suzuki K, Yamanaka H, Ebihara K, Sasaki A. Rapidly progressive malignant epithelioid angiomyolipoma of the kidney. JUrol 2002;168:190-1.
3. Yokoo H, Isoda K, Nakazato Y, Nakayama Y, Suzuki Y, Nakamura T, et al. Retroperitoneal epithelioid angiomyolipoma leading to fatal outcome. Pathol Int 2000;50:649-54.
4. Huang KH, Huang CY, Chung SD, Pu YS, Shun CT, Chen J. Malignant epithelioid angiomyolipoma of the kidney. J Formos Med Assoc 2007;106:S51-4.
5. Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. The past, the present, and the future. Virchows Arch 2008;452:119-32.
6. Cibas ES, Goss GA, Kulke MH, Demetri GD, Fletcher CD. Malignant epithelioid angiomyolipoma ('sarcoma ex angiomyolipoma') of the kidney: a case report and review of the literature. Am J Surg Pathol 2001;25:121-6.
7. Italiano A, Delcambre C, Hostein I, Cazeau AL, Marty M, Avril A, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol 2010;21:1135-7.
8. Brimo F, Robinson B, Guo C, Zhou M, Latour M, Epstein JI. Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. Am J Surg Pathol 2010;34:715-22.
9. Karbowniczek M, Henske EP. The role of tuberin in cellular differentiation: are B-Raf and MAPK involved? Ann N Y Acad Sci 2005;1059:168-73.
10. Pan CC, Chung MY, Ng KF, Liu CY, Wang JS, Chai CY, et al. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. J Pathol 2008;214: 387-93.
11. Wolff N, Kabbani W, Bradley T, Raj G, Watumull L, Brugarolas J. Sirolimus and temsirolimus for epithelioid angiomyolipoma. J Clin Oncol 2010;28:e65-8.